Abstract
A VARIETY of antisickling substances, both synthetic and naturally occurring, have been studied for their potential value as agents for the treatment of sickle cell disease. 3,4-dihydro-2, 2-dimethyl-2H-l-benzopyran-6-butyric acid (DBA), a chemically modified derivative of xanthoxylol isolated from Fagara zanthoxyloides, has been reported to prevent as well as reverse sickling of sickle cell anaemia erythrocytes1. 10 mM DBA was described as being able virtually to abolish sickling within a period of 30 min1. We have examined the effect of DBA on washed erythrocytes prepared from blood of sickle cell anaemia patients, and report here that we have been unable to demonstrate any antisickling effect of DBA.
Similar content being viewed by others
References
Ekong, D. E. U. et al. Nature 258, 743 (1975).
Honig, G. R., Farnsworth, N. R., Ferenc, C. & Vida, L. N. Lloydia 38, 387 (1975).
Elbaum, D., Nagel, R. L., Bookchin, R. M. & Herskovits, T. T. Proc. natn. Acad. Sci. U.S.A. 71, 4718 (1974).
Bertles, J. F., Dobler, J. Blood 33, 884 (1969).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
HONIG, G., VIDA, L. & FERENC, C. Effects in vitro of the proposed antisickling agent DBA. Nature 272, 833–834 (1978). https://doi.org/10.1038/272833a0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/272833a0
- Springer Nature Limited